Compare DraftKings Inc (DKNG) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Johnson & Johnson — how do they compare? DraftKings Inc trades at $19.55 (market cap $9.86B), while Johnson & Johnson trades at $261.54 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 62.7× DraftKings Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while DraftKings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DraftKings Inc for 55 Days and Johnson & Johnson for 129 Days on average.
| DKNG | JNJ | |
|---|---|---|
Market Cap | $9.86B | $618.09B |
Volume | 16,584,596 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $36.24 | $278.43 |
52-Week Low | $18.59 | $186.00 |
Typical Hold Time | 55 Days | 129 Days |
Enterprise Value | $10.80B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DraftKings (DKNG) trades at $19.58, down 7.4% recently and near a 52-week low of $18.95, reflecting bearish technical signals. The company achieved profitability in 2025 with $6.05B revenue and $3.71M net income, but Q2 2026 EPS missed estimates. Analyst consensus remains strongly bullish with a $33.13 price target, though high valuation multiples and recent earnings volatility pose concerns.
Long-term prospects are supported by revenue growth and strategic initiatives like the DKeX rollout and NHL sponsorship, targeting $1B EBITDA in 2026. However, risks include competitive pressures, regulatory uncertainty in markets like Brazil, and the stock's sensitivity to growth deceleration. Investors should weigh strong analyst optimism against fundamental execution risks.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
